secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amphastar Pharmaceuticals, Inc. (AMPH)
CIK:        0001297184
Form:       8-K
Filed at:   2021-08-20T23:59:59+00:00
Accession:  0001297184-21-000054
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 2.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Amphastar to acquire remaining ~15% of Nanjing subsidiary for $22.5M cash
-------------------------------------------------------------------------

- Signed SPA for ~15% stake in Amphastar Nanjing Pharmaceuticals (ANP) from QQ for ~$22.5M.
- Deal subject to regulatory approval; after closing, Amphastar will own 100% of ANP.
- QQ is controlled by COO/Chairman Mary Luo, CEO Jack Zhang, and family members.
- Proceeds: APCL $18.96M, Bill Zhang $3.37M, Chongqing Zhang $0.21M.
- Transaction price based on independent valuation and deemed fair by disinterested directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1297184/000129718421000054/0001297184-21-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1297184/000129718421000054/amph-20210819x8k.htm
  HTML page:      https://secwatch.observer/filing/0001297184-21-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer